Programmed cellular immunotherapeutic (Fate Therapeutics)

N/A

Report date: 2022/07/19 16:22:54

Base Information

Drug NameProgrammed cellular immunotherapeutic (Fate Therapeutics)
Drug Alias NameProgrammed mobilised peripheral blood cellsProTmune
ClassificationBiologics
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsGraft vs Host DiseaseMyelodysplastic SyndromesHematologic Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesThe Scripps Research Institute Inc
China Registration ClassN/A

Develop Information

Active CompaniesFate Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsGraft vs Host DiseaseMyelodysplastic SyndromesHematologic Neoplasms +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A